Evidence map›Paper›PMID 29535836›Full record

ArticleOncotarget2018

The absence of a novel intron 19-retaining

Abdulraheem Alshareef, Meredith S Irwin, Nidhi Gupta, Hai-Feng Zhang, Moinul Haque, Scott D Findlay, Bo Kyung Alex Seong, Justine Lai, Mohammed Rayis, Sadeq Al-Dandan and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Abdulraheem AlshareefDepartment of Applied Medical Sciences, Taibah University, Medina, Saudi Arabia.
Meredith S IrwinDivision of Haematology-Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
Nidhi GuptaDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Hai-Feng ZhangDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Moinul HaqueDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Scott D FindlayDepartment of Oncology, University of Alberta, Edmonton, Canada.
Bo Kyung Alex SeongDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.
Justine LaiDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Mohammed RayisDepartment of Pediatric Oncology, King Fahad Medical City, Riyadh, Saudi Arabia.
Sadeq Al-DandanDepartment of Anatomical Pathology, King Fahad Medical City, King Saud bin Abdulaziz University, Riyadh, Saudi Arabia.
Raymond LaiDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
University of Alberta · CAKing Fahd Medical City · SASickKids Foundation · CAUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ALK missense mutations are detected in 8% of neuroblastoma (NB) tumors at diagnosis and confer gain-of-function oncogenic effects. The mechanisms by which the expression of wild-type or mutant

Indexed as

alk-expressing human cancersanaplastic lymphoma kinaseintron-retention transcriptneuroblastomaprognostic markers

Identifiers

PMID29535836
PMCPMC5828214
OpenAlexW2784230285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.